A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple-negative Breast Cancer
Interventions: DRUG: AT regimen|DRUG: Tislelizumab|DRUG: Anlotinib
Sponsor: Sichuan Provincial People's Hospital